A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-hematologic Malignancies
Latest Information Update: 28 Nov 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 01 Sep 2006 Status change
- 19 Sep 2005 New trial record.